{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:51:40Z","timestamp":1790880700846,"version":"4.1.0"},"reference-count":27,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Alvotech Swiss AG, Z\u00fcrich, Switzerland"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2023,8,3]]},"DOI":"10.1080\/14712598.2023.2235263","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T06:12:12Z","timestamp":1689142332000},"page":"759-771","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":34,"title":["Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis"],"prefix":"10.1080","volume":"23","author":[{"given":"Steven R","family":"Feldman","sequence":"first","affiliation":[{"name":"Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, USA"},{"name":"Department of Dermatology, The University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliya","family":"Reznichenko","sequence":"additional","affiliation":[{"name":"Military Hospital (Military Unit A3309) of Military-Medical Clinical Center of Eastern Region, Zaporizhzhia, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Berti","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Duijzings","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Ruffieux","sequence":"additional","affiliation":[{"name":"Alvotech Swiss AG, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Otto","sequence":"additional","affiliation":[{"name":"Clinical and Medical Affairs, Alvotech Germany GmbH, J\u00fclich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halimu N","family":"Haliduola","sequence":"additional","affiliation":[{"name":"Clinical and Medical Affairs, Alvotech Germany GmbH, J\u00fclich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Leutz","sequence":"additional","affiliation":[{"name":"Clinical and Medical Affairs, Alvotech Germany GmbH, J\u00fclich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heimo","family":"Stroissnig","sequence":"additional","affiliation":[{"name":"Clinical and Medical Affairs, Alvotech Germany GmbH, J\u00fclich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"cit0001","unstructured":"EMA. Stelara summary of product characteristics, Janssen-Cilag International NV, Belgium. [cited 12 May 2015]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara#product"},{"key":"cit0002","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA). Report On The Deliberation Results. 17 Feb 2017; [cited 09 May 2023]. https:\/\/www.pmda.go.jp\/files\/000227668.pdf"},{"key":"cit0003","unstructured":"EPAR EMA. [cited 12 May 2015]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-eparproduct-information_en.pdf"},{"key":"cit0004","unstructured":"FDA. Stelara US-Prescribing Information. [cited 12 May 2015]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125261s150lbl.pdf"},{"key":"cit0005","unstructured":"Xian, Janssen. Stelara Chinese product information. [cited 12 May 2015]. https:\/\/www.xian_janssen.com.cn\/sites\/default\/files\/PDF\/13fu_jian_wu_si_nu_dan_kang_zhu_she_ye_shuo_ming_shu__20200311.pdf"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1009-0"},{"issue":"13","key":"cit0007","first-page":"S439","volume":"22","author":"McCamish M","year":"2016","journal-title":"Am J Manag Care"},{"key":"cit0008","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. [cited 3 Apr 2015]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf"},{"key":"cit0009","unstructured":"US Department of Health and Human Services. Biosimilars: questions and answers regarding implementation of the biologics price competition and innovation act of 2009. Guidance for industry. [cited 22 May 2017]. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM444661.pdf"},{"key":"cit0010","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for industry. [cited 22 May 2017]. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm291134.pdf"},{"key":"cit0011","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues. [cited 6 Jan 2016]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128686.pdf"},{"key":"cit0012","unstructured":"US Department of Health and Human Services. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance For Industry. [cited 12 May 2015]. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf"},{"key":"cit0013","doi-asserted-by":"crossref","unstructured":"Berti F, Wynne C, Stroissnig H, et al. Assessment of bioequivalence between candidate biosimilar AVT04 and reference ustekinumab. Presented At: AAD 2023; Mar 17-21, 2023; [cited 25 Apr 2023]. https:\/\/eposters.aad.org\/abstracts\/42601","DOI":"10.1016\/j.jaad.2023.07.496"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2215426"},{"key":"cit0015","unstructured":"EMA. Guidance on the management of clinical trials during the COVID-19 (Corona Virus) pandemic. [cited 12 Aug 2021]. https:\/\/ec.europa.eu\/health\/sites\/default\/fles\/fles\/eudralex\/vol-10\/guidanceclinicaltrials_covid19_en.pdf"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031237"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"cit0018","volume-title":"The psoriasis and psoriatic arthritis pocket guide","author":"van Voorhees A","year":"2016","edition":"4"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0386-y"},{"key":"cit0020","unstructured":"EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues 01 Jul 2015. EMEA\/CHMP\/BMWP\/42832\/2005 Rev.1. [Accessed 3 Aug 2020]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biologicalmedicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf"},{"key":"cit0021","unstructured":"EMA. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. 01\/12\/2014. CHMP\/BWP\/247713\/2012. [cited 3 Aug 2020]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guidelinesimilar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en1.pdf"},{"key":"cit0022","unstructured":"EMA. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use 1 Dec 2012. EMA\/CHMP\/BMWP\/86289\/2010. [cited 03 Aug 2020]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicityassessment-monoclonal-antibodies-intended-vivo-clinical-use_en.pdf"},{"key":"cit0023","unstructured":"FDA. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product, final guidance Dec 2016. [cited 3 Aug 2020]. https:\/\/www.fda.gov\/media\/88622\/download"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"cit0026","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Considerations in demonstrating interchangeability with a reference product: guidance for industry. May 2019. [cited 9 May 2023]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-guidance-industry"},{"key":"cit0027","unstructured":"EMA. Assessment report for Stelara. stelara-epar-public-assessment-report_en.Pdf (europa.eu). [cited 9 May 2023]. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/stelara-epar-public-assessment-report_en.pdf"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2023.2235263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T18:05:48Z","timestamp":1702749948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2023.2235263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8,3]]}},"alternative-id":["10.1080\/14712598.2023.2235263"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2023.2235263","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}